Drugs / CKD-388
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05189288 | Jan → Mar 2022 | chronic hepatitis B virus infection | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT04676893 | Feb → May 2021 | chronic hepatitis B virus infection | Chong Kun Dang Pharmaceutical | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CKD-388 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04676893 ↗ |